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Abstract
Effective tuberculosis (TB) vaccine should target tubercle bacilli with various metabolic
states and confer long-term protective immunity. In this study, we constructed a novel multi-
stage TB subunit vaccine based on fusion protein ESAT6-Ag85B-MPT64(190-198)-Mtb8.4-
HspX (LT69 for short) which combined early expressed antigens and latency-associated
antigen. The fusion protein was mixed with an adjuvant being composed of N, N’-dimethyl-
N, N’-dioctadecylammonium bromide (DDA) and polyriboinosinic polyribocytidylic acid
(PolyI:C) to construct subunit vaccine, whose immunogenicity and protective ability were
evaluated in C57BL/6 mice. The results showed that LT69 had strong immunogenicity and
high protective effect againstMycobacterium tuberculosis (M. tuberculosis) H37Rv aerosol
challenge. Low-dose (2 μg) of LT69 generated long-term immune memory responses and
provided effective protection, which was even higher than traditional vaccine BCG did at 30
weeks post the last vaccination. In conclusion, multistage subunit vaccine LT69 showed
high and long-term protection againstM. tuberculosis infection in mice, whose effect could
be enhanced by using a relative low dosage of antigen.
Introduction
Tuberculosis (TB) remains a major global health problem and ranks as the second leading
cause of death from an infectious disease [1]. Vaccination is still the most cost-effective
approach towards improving public health in both industrialized and developing countries [2].
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Mycobacterium bovis Bacillus Calmette-Gueerin (BCG) is the only TB vaccine for human use
in current, but its protective efficacy wanes significantly over a period of 10–15 years [3, 4].
BCG vaccination mainly induces effector memory T cells (TEM) that survive for a shorter
period of time than central memory T cells (TCM) [5], which may underlie the limited duration
of BCG vaccine protection [6]. Therefore, novel vaccines and vaccine strategy should aim at
inducing long-lasting T cell responses [7].
Subunit vaccines have been developed with the hope of boosting BCG-derived immunity so
as to provide a long period of protection [8]. These vaccines include viral vector-based vaccines
[9, 10] and recombinant proteins delivered with adjuvants. It was reported that the adjuvanted
recombinant protein induced more memory/multifunctional T cells that lead to long-term
immune memory responses compared to the viral vector in mouse and non-human primate
TB models [11]. Therefore, recombinant protein-based subunit vaccine is perhaps the promis-
ing vaccine to provide long-term protection against TB.
T cell mediated immune response is believed to play an important role againstM. tuberculo-
sis infection. In response to vaccination, the majority of the activated T cells differentiate into
antigen specific short-lived effector cells, whereas only a small proportion differentiates into
long-lived memory cells [12, 13]. Antigen stimulation is the primary factor to regulate the
diverse pattern of memory T cells [14]. Low-dose antigen and short-term antigen persistence
were reported mainly to induce central memory T cell formation and hence facilitate develop-
ment of long-term immunity in vivo [14, 15].
Our previous work showed that the combination of EAMM, which consists of four antigens
highly expressed in replicating bacilli, and MH, which consists of dormancy-related antigen
HspX, provided higher protective efficacy than EAMM or MH alone obviously [16]. These
results suggest that vaccines combining antigens from both proliferation and dormant stages
could generate broader immune responses and therefore could be more effective in eradicating
all stages ofM. tuberculosis. In this study, we fused EAMM and HspX together to construct a
new multistage protein ESAT6-Ag85B-MPT64 (190–198)-Mtb8.4-HspX with molecular
weight of 69kD, which was named as LT69. The immunogenicity and protective efficiency of it
were evaluated in mice model.
Materials and Methods
Ethics statement
Animal experiments were performed in accordance with the guidelines of Council on Animal
Care and Use. The protocols were approved by the Institutional Animal Care and Use Com-
mittee of Gansu University of Traditional Chinese Medicine (permit number: SYXK(Gan)
2013–001). Animals received free access to water and food throughout the study. During the
experiments, the vaccinated and infected mice were monitored every day. Mice were eutha-
nized by cervical dislocation.
Bacterial strains
BCG Denmark strain was provided by Lanzhou Institute of Biological Products.M. tuberculosis
H37Rv strain (ATCC 93009) was prepared by ABSL-3 Lab at Wuhan University. BCG andM.
tuberculosisH37Rv were grown in Middlebrook 7H9 supplemented with oleic acid albumin
dextrose catalase (OADC) (10% v/v) and glycerinum (0.5% v/v). Bacterial suspensions were
frozen and stored at -80 °C. Serial dilutions of the bacteria suspensions were plated on 7H11
OADC agar plates for colony forming units (CFU) counting before use.
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Animals
C57BL/6 female mice (6–8 weeks old) were purchased from Slaccas Inc. (Beijing, China) and
were maintained in special pathogen-free conditions in Gansu University of Traditional Chi-
nese Medicine. ForM. tuberculosisH37Rv challenge experiments, animals were kept in ABSL-
3 lab at Wuhan University.
pET30a(+)-ESAT6-Ag85B-MPT64(190–198)-Mtb8.4-HspX plasmid
construction
Recombinant pET30a(+)-Mtb8.4-HspX and pET30a(+)-ESAT6-Ag85B were produced as pre-
viously described [16]. The plasmid encoding ESAT6-Ag85B-MPT64(190–198)-Mtb8.4-HspX
was generated by inserting the gene fragments into the multiple cloning sites of pET30a(+) suc-
cessively as follows. Initially, the DNA sequences of MPT64(190–198)-Mtb8.4-HspX was gen-
erated by PCR amplification from pET30a(+)-Mtb8.4-HspX plasmid with the primer MMH F,
5’-3’GAAGATCTTTCGCAGTCACGAACGACGGGGTGATTAGGCTGTCGTTGACCGCA
(Bgl II) and the primer MMH R, 5’-3’TAGGCAAGCTTTCAGTTGGTG GACCGGAT (Hind
III), the sequence of MPT64190-198 is underlined. The fragment was cloned into the Bgl II and
Hind III site of pET30(+) to construct the plasmid pET30(+)-MPT64(190–198)-Mtb8.4-HspX.
ESAT6-Ag85B sequence was generated by PCR amplification from pET30a(+)-ESAT6-Ag85B
plasmid with the primer EA F, 5’-3’ CGGCATATGACAGAGCAGC AGTGGAA T (Nde I)
and EA R, 5’-3’ GAAGATCTGCCGGCGCCTAACGA ACTCTGGAG(Bgl II). Then this frag-
ment was cloned into the unique sites Nde I and Bgl II of the previously constructed pET30
(+)-MPT64(190–198)-Mtb8.4-HspX plasmid to get the last plasmid. The final plasmid was
transformed into the E. coli strain BL21 to express the fusion protein LT69.
Expression and purification of mycobacterial fusion proteins
E. coli BL21 expressing LT69 was incubated with 0.5 mM isopropyl β-D-thiogalactopyanoside
(IPTG) for 6 h at 25 °C. Then, cells were harvested and sonicated. Finally, the supernatant con-
taining the target protein LT69 was subjected to purification as below.
Two steps were involved in the purification of LT69. First, saturated ammonium sulfate was
added to the protein sample to 8% of saturation, and followed by centrifugation. The superna-
tant was discarded and the pellet was resuspended in buffer A (phosphate buffer, 20 mM;
pH7.4). The resuspended pellet was subjected to ammonium sulfate precipitation using 6%, 4%
and 2% saturation successively. The final precipitate was collected and resuspended in buffer A
containing 0.02 M arginine and 1 M urea. Second, the LT69 was further purified by a gel filtra-
tion chromatography (GFC) on Superdex 75 column. At last, the protein LT69 was eluted from
the resin with buffer B (phosphate buffer, 20 mM; sodium chloride, 0.15 M; pH7.4). Endotoxin
level of the fusion protein LT69 was quantified by Gel Clot Tachypleus Amebocyte lysate
(TAL) assay (Zhanjiang A&C Biological Ltd., Zhanjiang, China). MH and EAMMwere puri-
fied as described previously [16, 17].
Immunogenicity and protective efficacy of the fusion protein LT69 in
adjuvant of DDA-Poly (I:C)
Mice were injected with 10 μg of LT69 emulsified in an adjuvant being composed of N, N'-
dimethyl-N, N'-dioctadecylammonium bromide (DDA) (250 μg/dose; Sigma-Aldrich, Poole,
UK) and polyinosinic-polycytidylic acid [Poly (I:C)] (50 μg/dose; Sigma-Aldrich, Poole, UK)
subcutaneously with a total volume of 200 μl/mice. Mice received 10 μg of EAMM plus 10 μg
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of MH, BCG (5 × 106 CFU) and PBS were served as controls. BCG was injected once at week 0.
Other groups received three times inoculations at week 0, 2, and 4 respectively.
Six weeks after the last immunization, the levels of antigen-specific IFN-γ, IL-2 and antibod-
ies were analyzed. IFN-γ was tested using an enzyme-linked immunospot (ELISPOT) assay
following 20-h incubation of splenocytes with special antigens including ESAT-6 (10 μg/ml),
Ag85B (5 μg/ml), Mtb8.4 (10 μg/ml), HspX6 (10 μg/ml) and PPD (5 μg/ml). IL-2 secretion was
detected by ELISA assay from the spleen cells culture supernatant. The levels of IgG1 and
IgG2c antibodies against ESAT6 (10 μg/ml), Ag85B (5 μg/ml) and HspX (10 μg/ml) in mouse
sera were determined using ELISA assay as described previously [17].
Thirty weeks after the last immunization, mice were challenged with virulentM. tuberculosis
H37Rv via the respiratory route at approximately 50–100 CFU per mouse. For infection, frozen
bacteria stocks were thawed and diluted to 106 CFU/mL, and nebulized in an aerosol infection
chamber (Salter Labs, CA, USA) containing the mice. Infectious dose was determined by plat-
ing whole lung homogenates on day 1. Ten weeks later, the animals were euthanized, and lungs
and spleens were homogenised in saline and plated at 10-fold serial dilutions on Middlebrook
7H11 agar (BD, NJ, USA) enriched with OADC (BD, NJ, USA) and an antibiotic mixture
including carbenicillin, trimethoprim and amphotericin B (Sigma, MO, USA).
Immune memory responses induced by different doses of LT69
LT69 vaccine was used for vaccination in doses of 2 μg, 10 μg and 50 μg in 200μl separately.
Mice were vaccinated subcutaneously three times with 2 weeks apart. Control mice received
PBS or a single dose of 5 × 106 CFU BCG. Six weeks and twenty-four weeks after the last injec-
tion, the antigen specific IFN-γ secretion was detected by ELISPOT as described above.
Statistical analysis
The results were expressed as means ± SD. Data were compared using analysis of variance
(ANOVA) and SPSS13.0 software. Values of p< 0.05 were considered as statistically
significant.
Results
Expression and purification of LT69, EAMM and MH
The fusion protein LT69 could be expressed in E. coli in supernatant (Fig 1A) and was purified
by gradient salt fractionation and gel filtration chromatography successively (Fig 1B). The
fusion proteins EAMM and MH [17] were purified and confirmed by SDS-PAGE (Fig 1C) and
Western-blot (data not shown). At a concentration of 0.4 mg/mL LT69, the endotoxin level
was less than 2.5 EU/ml, which was lower than the limit for animal and in vitro experiment
required.
LT69 was of strong immunogenicity and high protective efficacy
With the stimulation of ESAT6, Ag85B, Mtb8.4 or PPD in vitro, the production of IFN-γ and
IL-2 by spleen cells from mice immunized with LT69 were higher than that from PBS, BCG
and EAMM+MH (p< 0.05) (Fig 2). With the stimulation of HspX, the IFN-γ secretions in the
group of LT69 were higher than PBS, and BCG groups, but the differences between the groups
of LT69 and EAMM+MH were not obvious (Fig 2A).
IgG1 and IgG2c antibody titers against antigens ESAT6, Ag85B and HspX and the relative
ratio of IgG2c titer to IgG1 titer in LT69 group were significantly higher than that of BCG
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group (p< 0.05) and almost as same as EAMM+MH group (Table 1). The antibody titers in
PBS control group were negative.
Furthermore, 30 weeks after the last vaccination, we detected the protective effect of LT69
vaccine using theM. tuberculosis H37Rv aerosol challenge model. Subunit vaccine LT0069 in
dose of 2 μg showed higher effective rate of protection againstM. tuberculosis than EAMM
+MH and BCG did (p< 0.05), with 1.17 log10 CFU decline in the lungs compared with PBS
control, while LT69 in 10 μg per dose showed the same protective efficacy as EAMM +MH and
BCG, reducing approximately 0.85 log10 CFU of the bacilli in lungs compared with PBS control
(Fig 3A).
Low-dose LT69 generated long-lived cellular immune responses
To examine the T cell immune memory induced by different dosages of LT69, mice were
vaccinated with three doses of LT69 (2 μg, 10 μg or 50 μg) separately. Antigen specific cellular
immune responses were detected twice at 6 and 24 weeks after the last immunization, respec-
tively. Six weeks after the last inoculation, all the LT69 vaccinated mice had high levels of IFN-
γ releasing from antigen stimulated splenocytes in vitro and there was no obvious difference
among them (Fig 4). However, 24 weeks after the last immunization, the 2 μg of LT69 vacci-
nated mice generated significantly higher levels of IFN-γ than the mice received 10 μg and
50 μg of the vaccine (p< 0.01), and the 10 μg group generated higher immune responses than
that of the 50 μg group (p< 0.05) (Fig 4). As for protective efficacy, 2 μg of LT69 immunization
reduced more bacteria load in lung tissues than BCG and EAMM+MH did, but 10 μg of LT69
did not show so strong protection (Fig 3A).
Fig 1. Expression and purification of LT69. (A) Expression of LT69 in E. coli. The LT69 protein was induced by IPTG in E. coli BL21 at 25°C for 6h.
Coomassie Blue-stained 12% SDS-PAGE of total E. coli lysate (lane 1), supernatant of E. coli lysate (lane 2), and sediment of E. coli lysate (lane 3). (B)
Purification of LT69. LT69 was purified by two steps, and finally its purity is beyond 90%. The figure shows a Coomassie Blue-stained 12% SDS-PAGE of
LT69 purified by gradient salt fractionation (lane 1) along with LT69 purified by gradient salt fractionation and gel filtration chromatography (lane 2, 3). M,
molecular weight. (C) Purified fusion proteins MH (lane 2) and EAMM (lane 3).
doi:10.1371/journal.pone.0130641.g001
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Discussion
In this study we recombined our previous fusion protein EAMM and MH together to construct
a novel multistage fusion protein LT69. We found that LT69 had at least the same levels of
Fig 2. The immunogenicity of LT69 vaccine in mice.C57BL/6 mice were immunized with 50μg or 10μg or
2μg of LT69 formulated in DDA/Poly(I:C) separately via subcutaneous injection three times (2 weeks apart)
or with a single dose of BCG (5×106 CFU). For EAMM+MH group, the mice received EAMM (10 μg) plus MH
(10 μg) in DDA/Poly(I:C). Six weeks after the final immunization, spleen cells were stimulated with ESAT6 (10
xg /ml), Ag85B (5 μg/ml), Mtb10.4 (10 μg/ml), HspX (10 μg/ml) and PPD (5 μg/ml) separately in vitro. (A) The
IFN-γ secretion in splenocytes. (B) The IL-2 secretion in splenocytes. Results are presented as means ± SD,
n = 4. * p < 0.05, relative to PBS, BCG; ** p < 0.05, relative to PBS, BCG and EAMM+MH groups
doi:10.1371/journal.pone.0130641.g002
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immunogenicity and protective efficacy againstM. tuberculosis infection as EAMM plus MH
did. Especially, low dosage of LT69 (2 μg/dose) induced higher long-term protective efficacy
than traditional BCG at 30 weeks post vaccination.
According to the Yin-Yang model proposed, in either active TB or latent TB, the internal
bacterial population consists of varying growing and non-growing sub-populations with differ-
ent metabolic states and these populations can interconvert with each other [18]. Therefore,
TB subunit vaccines should combine antigens in various growth stages ofM. tuberculosis so as
to provide protective immunity against bacteria in different metabolic states. In this study,
LT69 vaccine consists of four antigens (ESAT6, Ag85B, Mtb8.4, and HspX) and a CD8 epitope
(the 190–198 peptide of MPT64), which are the main immunodominant antigens expressed
separately in replicating and dormantM. tuberculosis. Mice receiving LT69 generated robust
antigens specific IFN-γ and IL-2 responses as well as high titers of antigen-specific antibodies,
indicating that the novel vaccine consisting of five antigens had strong immunogenicity and
the single antigens can be recognized well by LT69 induced immunity. Furthermore, LT69 had
at least the same level of protective efficacy againstM. tuberculosis infection as EAMM+MH
and BCG vaccine (Fig 4A). All these suggested that LT69 vaccine might be a promising subunit
vaccine to prevent TB by targeting several metabolic states of infected bacilli.
Besides generating broad and strong protective immunogenicity against infected bacilli with
different metabolic states, multi-component vaccine LT69 might also be predicted having high
population coverage.M. tuberculosis antigens could not be recognized by immune cells from
all TB patients because of the polymorphism of human leukocyte antigen (HLA) system. Vac-
cine combining more than one antigen has the advantage of being recognized by extensive
human populations. In addition, there is still the possibility that vaccine based solely on one
antigen may select forM. tuberculosis that do not express the antigen so as to generate immune
evasion. LT69 containing fiveM. tuberculosis antigens might be beneficial for vaccination of
genetically diverse human populations and overcoming antigen presentation evasion [19, 20].
Since T-cell mediated immunity provides critical protective immune response againstM.
tuberculosis infection [21, 22], the prime goal of TB vaccine development is to elicit effective
long-lasting memory T-cells which could respond quickly and strongly upon encounter with
M. tuberculosis [22, 23]. It has been reported that low dose of antigen favors the induction of
central memory T cells (TCM) while high dose of antigen tents to stimulate effector memory T
cells (TEM) or effective T cells formation [14, 24–26]. BCG vaccine mainly induces TEM that
survive for a shorter period of time than TCM [5], which may underlie the limited duration of
BCG vaccine protection [6]. In this study, we found that 24 weeks following immunization, the
2 μg LT69 vaccinated mice generated significantly higher levels of IFN-γ than the mice received
Table 1. Serological responses to antigens in LT69 vaccine immunized mice.
Anti-ESAT6 Anti-Ag85B Anti-HspX
IgG1 IgG2c IgG2c/IgG1 IgG1 IgG2c IgG2c/IgG1 IgG1 IgG2c IgG2c/IgG1
PBS - - - - - - - - -
BCG 2.00 < 2 - < 2 < 2 - < 2 < 2 -
EAMM+MH 4.25±0.71 4.33±0.79 1.01±0.03 3.66±0.52 2.00 0.56±0.09 3.88±0.57 0.56±0.09 0.62±0.1
LT69(2 μg) * 3.40± 1.14 4.51±0.62 1.4±0.38 3.96±0.52 3.43±0.15 0.88±0.14 4.18±0.15 0.88±0.14 0.75±0.04
LT69(10μg) * 4.48±0.67 4.41±0.60 0.95±0.07 4.10±0.25 3.13±0.62 0.77±0.19 4.56±0.52 0.77±0.19 0.67±0.04
LT69(50μg) * 4.55±0.3 4.31±0.69 0.91±0.15 4.41±0.25 3.12±0.62 0.71±0.17 4.41±0.81 0.71±0.17 0.63±0.2
*P < 0.05, relative to PBS and BCG groups
doi:10.1371/journal.pone.0130641.t001
Tuberculosis Subunit Vaccine LT69 Provides High Protection
PLOS ONE | DOI:10.1371/journal.pone.0130641 June 22, 2015 7 / 11
10 μg and 50 μg of the vaccine (p< 0.01), whereas the difference was not observed 6 weeks
post immunization. Furthermore, thirty weeks post vaccination, low-dose LT69 (2 μg/dose)
vaccination resulted in a 1.15 ± 0.09 log10 CFU reduction in lungs compared with PBS control,
better than high-dose LT69 (0.85 ± 0.03 log10 CFU reduction) and BCG vaccine (0.53 ± 0.06
Fig 3. The protective efficacy of LT69 againstM. tuberculosisH37Rv infection inmice.Mice were
immunized subcutaneously with two different doses (10 μg and 2 μg) of LT69 formulated in DDA-Poly I:C three
times at 2-wks interval or with a single dose of BCG (5×106 CFU). At the 34th week, 30 weeks after the last
vaccination, mice were aerosol-infected withM. tuberculosisH37Rv 50–100 CFU. Ten weeks later, the
protective efficacy was measured and was expressed as log10 of number of CFU in lungs (A) and spleens (B).
Results are presented asmeans ± SD from groups of seven mice. * p < 0.05, relative to PBS; ** p < 0.05,
relative to PBS, BCG and EAMM+MH groups.
doi:10.1371/journal.pone.0130641.g003
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log10 CFU reduction). However, the differences in spleens among the groups of low-dose
LT69 (1.01 ± 0.02 log10 CFU reduction), high-dose LT69 (0.78 ± 0.22 log10 CFU reduction)
and BCG vaccine (0.89 ± 0.12 log10 CFU reduction) were not obvious. The reason might be
that there are different memory T cell populations induced in different tissues following vac-
cines immunization. In addition, we challenged mice through respiratory tract, the bacteria
load in lungs represents the protective effect against the aerosol attack, while the bacteria load
in spleens might represent the protective effect against bacteria transmitted to spleen tissues
through blood. These results suggested that low-dose of LT69 immunization generated more
long-term T cell responses and consequently induced better protective efficacy than high-dose
of LT69 and BCG vaccine in lung. In consistent with this, relative low dosage of other TB vac-
cine or vaccine candidate, such as BCG [27] and H56 [28], were reported to induce more stable,
protective immunity than high dosages. The reason might be that low dosages of vaccine
induced development of TCM that led to long-term and high protection [14]. A recent study
also reported that the recombinant BCG ΔureC::hly vaccine-induced TCM played the critical
role on its long-term protection against pulmonary TB [6]. The dose related protective effect
and mechanism were also verified in infection of other pathogens, such as influenza virus [24],
simian immunodeficiency virus (SIV) [29], and Leishmania major [30].
In summary, multistage subunit vaccine LT69 consisting five antigens had strong immuno-
genicity and high protective efficacy againstM. tuberculosis. Low-dose of LT69 generated long-
term immune memory responses and showed higher protective efficacy againstM. tuberculosis
Fig 4. The T cell immune responses in mice immunized with different dosage of LT69.Mice were
immunized subcutaneously with three different doses (50 μg, 10 μg or 2 μg) of LT69 formulated in DDA-Poly
I:C three times at 2-wks interval or with a single dose of BCG (5×106 CFU), and the number of vaccine-
induced IFN-γ cells was determined at 6 and 24 weeks after the last immunization. Freshly isolated spleen
lymphocytes were plated in duplicate at 5×105 cell per well in 96 spot and incubated with ESAT6 (10 μg/ml),
Ag85B (5 μg/ml) and HspX (10 μg/ml) for 20h. IFN-γ production was determined using mouse IFN-γ
ELISPOT kits. Results are presented as means ± SD, n = 4
doi:10.1371/journal.pone.0130641.g004
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infection than BCG did at 30 weeks post vaccination. These findings have implications for
design of new effective TB vaccines and vaccination regimens in the future.
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